Mantle cell lymphoma and its management: where are we now?
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5–6% non-Hodgkin’s lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern, and blastoid variant), variety in disease progression, and treatment response, make this disease a research focus to both experimental oncology and clinical oncology. Overexpression of cyclin D1 and chromosome t(11,14) translocation are the known molecular biomarkers of this disease. Mantle cell international prognostic index (MIPI), ki-67 proliferation index, and TP53 mutation are emerging as the prognostic biomarkers. Epigenetic profile variance and SOX11 gene expression profile correlate with treatment response. Over the years, the treatment strategy has been gradually evolving from combination chemotherapy to combination of targeted therapy, epigenetic modulation therapy, and immunotherapy. In a surprisingly short period of time, FDA specifically approved 4 drugs for treating mantle cell lymphoma: lenalidomide, an immunomodulatory agent; Bortezomib, a proteasome inhibitor; and Ibrutinib and acalabrutinib, both Bruton kinase inhibitors. Epigenetic agents (e.g. Cladribine and Vorinostat) and mTOR inhibitors (e.g. Temsirolimus and Everolimus) have been showing promising results in several clinical trials. However, treating aggressive variants of this disease that appear to be refractory/relapse to multiple lines of treatment, even after allogeneic stem cell transplant, is still a serious challenge. Developing a personalized, precise therapeutic strategy combining targeted therapy, immunotherapy, epigenetic modulating therapy, and cellular therapy is the direction of finding a curative therapy for this subgroup of patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Mantle cell lymphoma and its management: where are we now?
- Date Crossref
- 30/01/2019
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
SUNY Upstate Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Penn State Cancer Institute pays non établi dans la noticeÉtablissement de santé
-
Penn State Milton S. Hershey Medical Center pays non établi dans la noticeÉtablissement de santé
-
Upstate University Hospital pays non établi dans la noticeÉtablissement de santé
-
State University Of New York Upstate Medical University Upstate Cancer Center pays non établi dans la noticeUniversité ou école supérieure
-
Pennsylvania State University College of Medicine Penn State Hershey Cancer Institute pays non établi dans la noticeUniversité ou école supérieure
SUNY Upstate Medical University, Penn State Cancer Institute et Penn State Milton S. Hershey Medical Center, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.